Deep search
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
FDA, obstructive sleep apnea
FDA approves first medication for obstructive sleep apnea, which also promotes weight loss
The FDA approved a new drug treatment for obstructive sleep apnea that improves the condition through weight loss. Sleep expert Dr. Wendy Troxel discusses the impact of the new development.
Zepbound Weight Loss Medication Approved by FDA to Treat Sleep Apnea
The Food and Drug Administration (FDA) announced the approval of the weight loss drug Zepbound, generically known as tirzepatide, to help people treat obstructive sleep apnea.
FDA approves Zepbound for sleep apnea in patients with obesity
The US Food and Drug Administration has approved Zepbound (tirzepatide) as the first prescription medication for the treatment of obstructive sleep apnea (OSA).
Zepbound Gets FDA Approval to Treat Sleep Apnea
The obesity medication Zepbound can be used on-label to treat obstructive sleep apnea in adults with obesity, the FDA announced today.
F.D.A. Approves Weight Loss Drug to Treat Obstructive Sleep Apnea
Zepbound is the first prescription drug approved specifically to treat the common condition. The Food and Drug Administration on Friday approved the weight loss drug Zepbound to treat obstructive sleep apnea. It is the first prescription medication approved to treat the common sleep disorder.
FDA approves anti-obesity drug as first sleep apnea medication
The US FDA approved Eli Lilly's Zepbound as the first ever medication for obstructive sleep apnea for patients who also have obesity
This Weight Loss Drug Could Also Treat Sleep Apnea
If you have sleep apnea and obesity, tirzepatide Zepbound may offer relief and support weight loss. Ask your doctor if it’s a good fit.
Obesity Drug Zepbound Approved for Obstructive Sleep Apnea
The US Food and Drug Administration approved a new indication for Eli Lilly’s formulation of tirzepatide to treat moderate to severe OSA in people with obesity.
FDA Approves Zepbound for Obstructive Sleep Apnea
FDA has approved the first prescription drug, Zepbound, for treating moderate to severe obstructive sleep apnea (OSA) in adults with obesity.
2d
on MSN
Sleep Apnea Device Maker Stocks Slide on FDA Ruling for Eli Lilly's Zepbound
Key Takeaways Shares of ResMed and Inspire Medical Systems fell after the FDA approved Eli Lilly's weight-loss drug Zepbound ...
USA Today
5d
The popular weight-loss drug Zepbound can now be used to treat sleep apnea
Zepbound is the first medication approved to treat patients with
obstructive
sleep
apnea
, said Sally Seymour, the FDA's director of the division of pulmonology, allergy and critical care.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Trending now
Iran restores access
Official national bird of US
Discharged from hospital
Bird flu at Wash. sanctuary
FDA sets highest risk level
Russia sentences US man
Eye drops recalled
Sues VMware over patents
Nolan’s next film revealed
ISR admits to killing Haniyeh
Banks sue Federal Reserve
AL sheriff seeks FBI probe
Packers clinch playoff spot
Music producer Perry dies
Judge delays trial
Baldwin's legal case ends
Female Athlete of the Year
Calls for peace in Ukraine
Boat explosion in Florida
CFPB sues Rocket Homes
Ambassador to Panama
NC man charged w/ murder
Biden signs defense bill
Vows more weapons to UKR
Sudan famine spreading
Pakistani airstrikes on AFG
Rebuild gets start date
To honor 3 NFL assistants
Judge blocks parts of AR law
NYC congestion pricing
Former Hamas hostage dies
Related topics
Zepbound
India
Food and Drug Administration
Tirzepatide
Eli Lilly
Feedback